ITGB2 and non-small cell lung carcinoma: Together, these results suggest that lncRNA ITGB2-AS1 enhances resistance to cisplatin by suppressing p53-mediated ferroptosis via activation of the FOSL2 /NAMPT axis in NSCLC [176].